To hear about similar clinical trials, please enter your email below
Trial Title:
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
NCT ID:
NCT06538337
Condition:
Endometrial Cancer
Cervical Cancer
Conditions: Official terms:
Uterine Cervical Neoplasms
Endometrial Neoplasms
Conditions: Keywords:
endometrial
cervical
SBRT
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Intervention model description:
Single arm, non-randomized, trial of adjuvant SBRT to the pelvis with adaptive planning
using CT or MRI guidance for endometrial and cervical cancers
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Radiation
Intervention name:
External beam Radiotherapy
Description:
Five fractions of radiation therapy using adaptive planning and CT or MRI guidance (6 Gy
per fraction) delivered once every other day excluding weekends and holidays
Arm group label:
Hypofractionated External beam Radiotherapy
Other name:
Hypofractionated External beam Radiotherapy
Summary:
After surgery to remove the main endometrial and/or cervical tumor, most women receive
radiation therapy. This study uses hypo-fractionated radiation therapy, which is a type
of radiation therapy in which the total prescribed dose of radiation is delivered in
fewer but larger doses than conventional or standard radiotherapy.
This research study aims to determine if hypo-fractionated radiation therapy given after
surgery can improve treatment tolerability (i.e., fewer treatments) with comparable side
effects.
Participants will be in the study for about 5 years:
Radiation therapy:
- 5 daily treatment sessions of MRI or CT-Guided Stereotactic Body Radiation Therapy
(SBRT).
- Each treatment session will occur on a weekday (typically consecutive weekdays) and
will last approximately an hour.
Treatment Follow-Up:
- Check-up Appointment and answer questions at 3 months post RT
- Check-up Appointments with physical exam every 6 months (+/- 4 weeks) for up to 5
years.
Detailed description:
The investigators hypothesize that adaptive planning with either computed tomography (CT)
or magnetic resonance imaging (MRI) guidance may offer improved SBRT plans for
postoperative gynecological cancer patients due to issues with anatomic variation between
and during fractions of radiation therapy. Treatment on an MRI-guided linear accelerator
with adaptive planning capabilities has been shown to significantly improve acute
toxicity in the setting of prostate SBRT compared to conventional linear accelerators.10
The investigators, therefore, propose using adaptive planning with CT- or MRI-guidance to
deliver 30 Gy in 5 fraction adjuvant SBRT to the pelvis for endometrial and cervical
cancer patients.
Stereotactic Body Radiation Therapy (SBRT) with adaptive planning will be delivered
following surgical resection of the primary tumor. Patients will receive 6.0 Gy x 5
fractions delivered once every other day. Patients will not be treated on weekends or
holidays as is standard practice for radiation treatments.
Patients will be seen by the radiation oncologist within the first 3 months after
completion of radiation therapy. For patients who live a distance far enough away from
the University of California at Los Angeles (UCLA) where travel would be challenging for
the patient, a phone or telemedicine follow-up will be considered acceptable. After this,
follow-up will be performed every 6 months (+/- 4 weeks) for 5 years following completion
of radiotherapy. Patients will be followed clinically and/or radiographically per
physician discretion.
SCHEMA
Diagnosis of endometrial or cervical cancer
Surgical resection of primary tumor
Multidisciplinary discussion and recommendation for adjuvant radiotherapy to the pelvis
Patient enrollment in HERA clinical trial
Simulation scans to plan post-operative radiotherapy
Five fractions of radiation therapy using adaptive planning and CT or MRI guidance (6 Gy
per fraction) delivered once every other day excluding weekends and holidays
Follow-up within 3 months of completion of radiotherapy
Follow-up every 6 months (+/- 4 weeks) until 5 years of completion of radiotherapy
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Histologically confirmed endometrial or cervical cancer
- Surgical resection of the primary tumor
- International Federation of Gynecology and Obstetrics (FIGO) Stage IA-IVB
endometrial cancer OR FIGO Stage IA-IIA cervical cancer that meets indications for
receiving adjuvant pelvic radiotherapy alone as standard of care
- Age ≥ 18 years old
- Karnofsky performance status (KPS) ≥ 60 or Eastern Cooperative Oncology Group (ECOG)
0-2
Exclusion Criteria:
- Must not meet indications for receiving concurrent chemotherapy as standard of care
- Active treatment of a separate malignancy
- History of prior irradiation to the area to be treated
Gender:
Female
Gender based:
Yes
Gender description:
Study considers endometrial and cervical cancer which are defined as physically occurring
in the uterus and the cervix.
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University of California at Los Angeles
Address:
City:
Los Angeles
Zip:
90095
Country:
United States
Status:
Recruiting
Contact:
Last name:
Christy Palodichuk
Phone:
310-794-2971
Email:
cpalodichuk@mednet.ucla.edu
Contact backup:
Last name:
Vincent Basehart
Phone:
310-267-8954
Email:
vbasehart@mednet.ucla.edu
Investigator:
Last name:
Puja S. Venkat, MD
Email:
Principal Investigator
Start date:
July 24, 2024
Completion date:
July 26, 2032
Lead sponsor:
Agency:
Jonsson Comprehensive Cancer Center
Agency class:
Other
Source:
Jonsson Comprehensive Cancer Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06538337